Cedars-Sinai's AI tool delivered 24/7 care to 42,000 patients. Now, doctors can focus on treatment, not paperwork.
The platform aims to reduce wait times and administrative tasks, improving care delivery.
This article is part of " CXO AI Playbook" — straight talk from business leaders on how they're testing and using AI.
Cedars-Sinai is a nonprofit healthcare organization based in Los Angeles. It's comprised of hospitals, clinics, and research facilities. Founded in 1902, Cedars-Sinai has more than 40 locations, employs over 4,500 physicians and nurses, and serves more than 1 million patients every year.
Situation analysis
Caroline Goldzweig, chief medical officer of Cedars-Sinai Medical Network, told Business Insider that the organization wanted to expand patients' access to primary care in a more efficient and convenient way. For instance, sometimes there are lengthy wait times for in-person doctor's appointments.
At the same time, Goldzweig said the organization was looking to reduce the administrative burden on physicians, including patient intake and data entry, so that they could focus on providing care.
To address these challenges, the organization launched Cedars-Sinai Connect in 2023. CS Connect is an artificial intelligence -powered virtual platform where patients can access healthcare support 24/7.
Goldzweig said the AI technology allows healthcare providers to better support their patients while improving the speed of care delivery. "The other exciting thing is the ability to offer patients care in ways that meet their needs," she said.
Key staff and partners
Goldzweig told Business Insider that CS Connect was built using K Health, a digital healthcare company providing AI-powered primary and urgent care services. Cedars-Sinai's information technology teams worked with K Health to sync patients' electronic health records into the platform, she said.
Cedars-Sinai's enterprise data intelligence and digital strategy teams were also involved in creating CS Connect. They continue to help manage it.
AI in action
The goal of the AI tool is to enable providers to spend more time counseling patients and making treatment decisions, rather than doing patient intake.
To access the AI features, patients log into CS Connect via a mobile app or its website. Goldzweig said a chat feature then starts asking the user questions about their symptoms.
The AI algorithm compares the patient's responses to their existing medical records and the records of other patients in the system who had similar symptoms. It then asks more detailed questions about a patient's specific health problems. The chatbot, for example, may prompt the patient to submit photos of their sore throat or rash.
Goldzweig said the chat function is similar to how a physician might identify a patient's ailment.
The AI then summarizes the patient's information — a task that usually demands manual effort from physicians — and recommends a treatment.
The data collected by CS Connect is "part of the efficiency process," Goldzweig said. "It allows the physicians to review it, to understand what's going on, and to validate things with the patient — ask a couple of clarifying questions and maybe get a little bit more history."
Physicians can choose to disagree with the AI's recommendations. Goldzweig said either way, they're required to sign off on each patient's treatment plan.
Did it work, and how did leaders know?
Goldzweig told BI that about 42,000 individual patients have used CS Connect.
In April 2025, Cedars-Sinai published a study in the journal Annals of Internal Medicine comparing AI treatment recommendations in CS Connect with final recommendations from doctors.
The study reviewed 461 physician-managed visits with AI recommendations for respiratory, urinary, vaginal, eye, and dental symptoms. Results showed that when AI and physician recommendations differed, the AI suggestions were often rated as higher quality.
The study found that 77% of AI recommendations were rated as optimal, while 67% of physicians' decisions were rated optimal.
For example, patients with recurring urinary tract infections sometimes encounter antibiotic resistance. Goldzweig said the AI was successful at identifying these patients and recommended a bacterial culture before prescribing antibiotics. In contrast, doctors sometimes prescribe medication without testing, which she said could result in the infection coming back.
Goldzweig added that the study suggests that the AI tool tends to be more guideline-focused, while physicians have the ability to adapt medical guidelines based on the nuance of a patient's case.
Goldzweig said the study has limitations, though. It examined only a few medical conditions and didn't factor in the nuance of individual patient cases. Another limitation is that the medical chart reviewers could see whether the recommendation was made by the AI or a physician.
Cedars-Sinai is working to expand CS Connect. The organization is piloting remote patient monitoring technology using AI to help people manage chronic diseases, like high blood pressure. It's also planning to use the AI technology to connect in-person urgent care visits with virtual care.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Why Did Micron Stock Drop Today?
Key Points Samsung says the market for HBM memory for artificial intelligence (AI) functions is getting oversupplied. Samsung will cut prices on the most powerful HBM3E product in an attempt to win market share. Wells Fargo says this is bad news for Micron. 10 stocks we like better than Micron Technology › Shares of computer memory-maker Micron Technology (NASDAQ: MU) tumbled 5.2% through 11:25 a.m. ET Thursday -- but as far as I can tell, it wasn't anything Micron did to deserve this. Instead, it was Samsung that's to blame. What Samsung said about high-bandwidth memory (HBM) As WCCFTech reports this morning, Samsung has just announced it's lowering prices on HBM3E (that's "High Bandwidth Memory 3 Enhanced," currently the most capable kind of HBM memory, designed for use in artificial intelligence and machine learning). Samsung explained that on the one hand, it hasn't been able to win as much HBM business from Nvidia (NASDAQ: NVDA) as it would like, while on the other hand, the HBM market seems oversupplied right now. And the solution to both problems -- to help Samsung move product -- is to lower prices. Is Micron stock a sell? For Micron, this poses a problem -- because Micron also wants to sell HBM3E memory, and now Samsung has effectively declared a price war in the HBM market. In order to fight it, Micron will have to lower its own prices (hurting Micron's revenue and profit), or else it will lose market share to Samsung (also hurting Micron's revenue and profit!) And if that sounds like a lose-lose proposition for Micron, that's because it is. In a note on The Fly this morning, Wells Fargo warned that Samsung's action will "impact market prices," drying up much of the premium in prices between HBM3E and plain-vanilla DRAM memory, perhaps as early as H2 2025 (i.e., now). Priced at just 20x trailing earnings, Micron stock may not look too expensive. But if profits are about to dry up as Samsung's price cuts take hold, Micron stock could look expensive in a hurry. Savvy investors might want to sell before that happens. Should you invest $1,000 in Micron Technology right now? Before you buy stock in Micron Technology, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Micron Technology wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Wells Fargo is an advertising partner of Motley Fool Money. Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy. Why Did Micron Stock Drop Today? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Microsoft capex to exceed $30B this quarter, CFO says
This story was originally published on CFO Dive. To receive daily news and insights, subscribe to our free daily CFO Dive newsletter. Dive Brief: Microsoft expects its capital expenditures for its current quarter to exceed $30 billion, driven by 'the continued strong demand signals' the software giant is seeing, CFO Amy Hood said Wednesday. The remarks came as the company reported $281.7 billion in total revenues for its last fiscal year ended June 30, a 15% year-over-year spike. For the current fiscal year, Microsoft anticipates that it will deliver 'another year of double-digit revenue and operating income growth,' according to Hood. 'We will continue to invest against the expansive opportunity ahead across both capital expenditures and operating expenses given our leadership position in commercial cloud, strong demand signals for our cloud and AI offerings, and significant contracted backlog,' she said during an earnings call. Dive Insight: On the heels of the better-than-expected quarterly earnings, Microsoft's stock price jumped 5% on Thursday, pushing the company's valuation beyond the $4 trillion mark, according to a CNBC report. The company joined chipmaker Nvidia, which hit $4 trillion for the first time earlier in July, the report said. 'If this growth is maintained, it significantly reduces the risk that Microsoft would need to rethink its massive AI-related CAPEX, even if competitive pressure increases,' Thomas Monteiro, senior analyst at said in emailed comments. 'In other words, the company's ability to balance heavy AI investment with margin expansion shows it can scale efficiently into FY26, regardless of external challenges,' he added. Microsoft and other tech giants continue to bet heavily on AI as investors eagerly look for signs that its paying off. Meanwhile, economic uncertainty triggered by President Donald Trump's on-again, off-again tariff measures has created added pressure for big tech firms. For its fiscal 2025 third quarter ended March 31, Microsoft's capex, including finance leases, totaled $21.4 billion. That amount was 'slightly lower than expected due to normal variability from the timing of delivery of data center leases,' Hood said during an earnings call in late April. At the time, Hood said Microsoft expected its capex to grow at a slower pace in its upcoming fiscal year starting in July. This came after the company confirmed a pullback in AI data center projects. The company's capex during its most recent quarter was $24.2 billion, Hood said on Wednesday. Reiterating comments she made earlier this year, Hood said Microsoft's capex growth in the current fiscal year will moderate. 'Due to the timing of delivery of additional capacity in H1, including large finance lease sites, we expect growth rates in H1 will be higher than in H2,' the finance chief said. Recommended Reading Microsoft capex to grow at slower rate, CFO says
Yahoo
an hour ago
- Yahoo
Tesla (TSLA) a ‘Buy' as Pullback Triggers Favorable Risk-Reward: TD Cowen Analyst
Tesla, Inc. (NASDAQ:TSLA) is one of the best AI stocks to buy, according to billionaire Stanley Druckenmiller. On July 24, TD Cowen analyst Itay Michaeli reiterated a 'Buy' rating on the stock and a $374 price target. david-von-diemar-ZBWn5DvO0hg-unsplash The bullish stance comes as the analyst reiterates that the recent dip pullback has tilted the stock's risk/reward favorably amid emerging new catalysts. The electric vehicle giant has already announced it has started building its more affordable model, with volume production planned for the second half of the year. The company plans to ramp up production of the affordable model, having suffered a major blow with the signing into law of the One Big Beautiful bill Act. With the new bill, there will no longer be a $7,500 tax credit that was the catalyst behind Tesla ramping up sales of its high-end models. To mitigate the expiration of the tax credits, Tesla has also confirmed plans to ramp up production of its purpose-built robotaxi, starting in 2026. Tesla, Inc. (NASDAQ:TSLA) designs, manufactures, sells, and leases electric vehicles, as well as energy generation and storage systems. It also leverages artificial intelligence technology to train cars to drive themselves and create useful humanoid robots. While we acknowledge the potential of TSLA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 11 Best 52-Week High Stocks to Buy Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data